D-0530-2020 Class II Ongoing
FDA drug recall D-0530-2020 was initiated by AuroMedics Pharma LLC on Nov 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups. The recall status is ongoing. Affected quantity: 26,736 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 4, 2019
- Initiation Date
- Nov 6, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 26,736 bottles
Product description
Aurobindo Ranitidine Capsules 150 mg, 500 count bottle, Rx Only Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520 NDC 59651-144-05
Reason for recall
CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.
Distribution pattern
nationwide
Code information
RA1518002-B Jul 2020 RA1518003-A Jul 2020 RA1518004-A Aug 2020 RA1518005-A Aug 2020 RA1518007-A Sep 2020 RA1518008-A Sep 2020 RA1518009-A Sep 2020 RA1518010-A Oct 2020 RA1518011-A Nov 2020 RA1518012-A Nov 2020 RA1518013-A Nov 2020 RA1518014-A Nov 2020 RA1518015-A Nov 2020 RA1519003-B May 2021 RA1519004-A May 2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0530-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026